Kornimate/medical-research-clean huggingface dataset:
multimodal endoscopic image fusion for assessing infiltration in superficial esophageal squamous cell carcinoma

Conditions: Esophageal Neoplasms Malignant

Summary: the objective of this project is to pioneer a novel protocol for the adjunctive screening of early-stage esophageal cancer and its precancerous lesions. the anticipated outcomes include simplifying the training process for users, shortening the duration of examinations, and achieving a more precise assessment of the extent of esophageal cancer invasion than what is currently possible with ultrasound technology. this research endeavors to harness the synergy of endoscopic ultrasound (eus) and magnifying endoscopy, augmented by the pattern recognition and correlation capabilities of artificial intelligence (ai), to detect early esophageal squamous cell carcinoma and its invasiveness, along with high-grade intraepithelial neoplasia. the overarching goal is to ascertain the potential and significance of this approach in the early detection of esophageal cancer. the project's primary goals are to develop three distinct ai-assisted diagnostic systems: an ai-driven electronic endoscopic diagnosis system designed to autonomously identify lesions. an ai-based eus diagnostic system capable of automatically delineating the affected areas. a multimodal diagnostic framework that integrates electronic endoscopy with eus to enhance diagnostic accuracy and efficiency.

the study was executed in two distinct phases. the initial phase, designated as the modeling phase (phase 1), involved a retrospective analysis of eligible subjects from a consortium of medical institutions, including the first affiliated hospital of naval medical university, west china hospital of sichuan university, provincial hospital affiliated to shandong first medical university, the first affiliated hospital of soochow university, the first affiliated hospital of henan university of science and technology, and the first affiliated hospital of shihezi university, all selected prior to january 1, 2024. the second phase, known as the real-world evaluation phase (phase 2), prospectively enrolled consecutive patients who were scheduled to undergo magnometric endoscopy and eus at the aforementioned hospitals between april 2024 and june 2024.

Eligibility criteria:
inclusion criteria: patients requiring magnifying endoscopy and endoscopic ultrasonography. individuals of either sex, aged 18 years or older. exclusion criteria: inability to complete esophageal electronic endoscopy. absence of biopsy or surgery, resulting in unobtainable pathological results. patients who have undergone endoscopic lesion destruction or piecemeal resection, preventing the acquisition of an en bloc resection sample. patients with significant endoscopic, imaging, or pathological evidence of advanced esophageal cancer. patients presenting with marked esophageal stenosis or dilatation. individuals with a history of other malignancies. patients who have received neoadjuvant radiotherapy. patients who declined to participate in the study and did not provide informed consent.

Keywords: esophageal neoplasms multimodality endosonography
comprehensive assessment of neurodegeneration and dementia

Conditions: Dementia

Summary: this is a 5-year observational study recruiting sixteen hundred and fifty individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group of six hundred and fifty aged matched individuals without cognitive deficits. participants will be recruited at sites across canada and will undergo assessments and provide biological samples at baseline and two years after baseline.

this is a 5-year observational study. sixteen-hundred and fifty (1650) subjects, between the ages of 50 and 90,years old, with subjective cognitive impairment, mild cognitive impairment, mild cognitive impairment with subcortical vascular lesions, alzheimer's disease, mixed dementia, lewy body dementia, parkinson's disease dementia, parkinson's disease with mild cognitive impairment and frontotemporal dementia, as well as 650 healthy elderly subjects without cognitive complaints or deficits, will be enrolled into this study from up to 30 centres across canada. all subjects involved in the study will undergo rigorous evaluations at baseline, including clinical assessment, neuropsychological assessment, genomics and neuroimaging. biological samples from blood, saliva, urine, fecal matter, buccal cells and cerebrospinal fluid will be collected, stored, and analyzed. basic follow-up determining if there has been any change in their diagnosis will be carried out annually and longitudinal re-evaluation will be carried out after two years.

Eligibility criteria:
inclusion criteria: * has subjective or objective cognitive impairment * written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver/family member) * sufficient proficiency in english or french to undertake self report and neuropsychological testing * geographic accessibility to the study site * must have a study partner who can participate as required in the protocol (provide corroborative information) exclusion criteria: * the presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, parkinson's disease (other than for the parkinson's/lewy body dementia cohort), and other rarer brain illnesses * ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures * symptomatic stroke within the previous year * moca \< 13 * unable to undergo mri scan due to medical contraindications or inability to tolerate the procedure
evaluate the efficacy and safety of the cilostazol-coated biomimics 3d stent system in patients with peripheral arterial occlusive disease

Conditions: Peripheral Arterial Disease

Summary: an exploratory evaluation of the efficacy and safety of clz-bm3d for the treatment of symptomatic peripheral occlusive arterial disease of the superficial femoral artery or proximal popliteal artery

this study demonstrate an exploratory evaluation of the efficacy and safety of clz-bm3d for the treatment of symptomatic peripheral occlusive arterial disease of the superficial femoral artery or proximal popliteal artery

Eligibility criteria:
inclusion criteria: * patients with an ankle-brachial index (abi) of 0.90 or less in the target lower extremity at rest. * patients with stenotic lesions (target lesions) requiring treatment of sfa or ppa. * patients with rutherford classification 2, 3, or 4. * the reference vessel diameter of the target lesion is between 4 mm or more and 5 mm by operator's visual estimate. * the total length of target lesion measure ≦50㎜ by operator's visual estimate. * target lesion lumen stenosis is \>70% diameter stenosis by operator's visual estimate. exclusion criteria: * patients with a history of surgical or endovascular treatment (including any percutaneous transluminal balloon angioplasty, stenting, atherectomy, or bypass) of the target lesion or vessel prior to enrollment in this study. however, a history of balloon dilatoplasty with poba is acceptable if it was performed earlier than 12 months prior to enrollment. * patients with a history of major amputation of the target lower extremity. * patients with another stenotic lesion in the target or contralateral lower extremity other than the target lesion that is judged to require surgery or endovascular treatment at the time of consent or within 12 months after the procedure. however, if the patient has another stenotic lesion in the iliac artery other than the target lesion, treatment of the iliac artery lesion (poba and stenting) is allowed at the time of the study procedure. * patients with acute coronary syndrome or stroke/cerebrovascular event within 3 months prior to obtaining consent. * patients with coagulopathy. * patients with renal insufficiencyor on dialysis. * patient who administered orally cilostazol within 7 days prior to the study procedure.
thalidomide therapy for veoibd

Conditions: Inflammatory Bowel Diseases

Summary: this is a single center, observational study to investigate the clinical outcomes of thalidomide treatment for very early onset inflammatory bowel disease

very early onset inflammatory bowel disease (veoibd) refers to ibd diagnosed before 6 years of age. veoibd comprises a distinct subset of pediatric ibd characterized by stronger genetic predisposition, predominant colonic involvement, more extensive inflammation, more severe course, and peculiar response to treatments. previous studies have been demonstrated that thalidomide, an oral molecule with immunomodulatory, antiangiogenic, and tnf-suppressing properties, is an effective and safe treatment for adults and children with ibd refractory to conventional therapies. this study is aimed to evaluate the efficacy and tolerance of thalidomide in veoibd.

Eligibility criteria:
inclusion criteria: * diagnosed with inflammatory bowel disease * disease onset less than 6 years old * pediatric crohn's disease activity index (pcdai)\>30 or pediatric ulcerative colitis activity index (pucai)\>35 * patients and their legal guardians were willing to receive thalidomide treatment and participate in this study. exclusion criteria: * liver dysfunction * allergy to thalidomide * with neuropathy * with thrombosis * thalidomide treatment in the previous 30 days * biologics treatment in the previous 8 weeks * not suitable participated in this study
oral and iv baclofen in adult volunteers

Conditions: Baclofen Withdrawal Syndrome

Summary: the primary objective of this study is to characterize baclofen pharmacokinetics following oral and intravenous administration in patients who are on chronic oral baclofen therapy. the secondary objective is to determine the safety profile of an iv baclofen formulation. this study is a randomized crossover study with two treatment arms. all subjects will receive a dose of oral baclofen and a dose of iv baclofen on separate study days. whether the oral or intravenous form is given on the first study day will be randomized in a 1:1 manner. the pharmacokinetic and tolerability information gained from this study will support the development of further studies to assess the use of iv baclofen to prevent or treat baclofen withdrawal syndrome.


Eligibility criteria:
inclusion criteria: subjects will be eligible to participate in the study if all of the following conditions exist: 1. males and females between the ages of 18-65. 2. subjects are capable of giving informed consent. 3. female subjects must be post-menopausal for at least 1 year, or surgically incapable of bearing children, or practicing at least one or more of the following methods of contraception for three months prior to, and during the study: hormonal, intrauterine device (iud), or barrier method in combination with a spermicide. 4. subject should be medication free, other than study drug, for 48 hours before through 24 hours after study drug administration. if the need for medication is identified during this time period, it will be discussed with and approved by the pi. - exclusion criteria: subjects will be excluded from participation in the study if any of the following conditions exist: 1. women who are pregnant. 2. women who are breast feeding. 3. subject has a history of intolerance to iv administration of medication. 4. subject has a known hypersensitivity to baclofen. 5. subject has a significant history of cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal or hepatic disease 6. subject has taken or used any investigational drug or device in the 30 days prior to screening. 7. subject has taken either prescribed or over the counter medication for 48 hours prior to baclofen administration on either of the study days. 8. subject reveals clinically significant abnormalities on screening laboratory tests. 9. subject is a non-english speaker, such that ability to ascertain neurological status would require an interpreter.

Keywords: baclofen, withdrawal, interuption, spasticity, pharmacokinetics, tolerability, intravenous, oral
ath-1017 for treatment of mild to moderate alzheimer's disease

Conditions: Alzheimer Disease; Dementia of Alzheimer Type

Summary: this study is designed to evaluate safety and efficacy of fosgonimeton (ath-1017) in the treatment of mild to moderate alzheimer's disease with a randomized treatment duration of 26-weeks.

the study is designed to evaluate safety and efficacy of ath-1017 in mild to moderate ad subjects, with randomized, parallel-arm treatment duration of 26 weeks, and based on clinical diagnostic criteria of alzheimer's disease. clinical efficacy is demonstrated by improvement in cognition and global/functional assessments comparing treatment to placebo.

Eligibility criteria:
key inclusion criteria: * age 55 to 85 years * mild-to-moderate ad dementia subjects, mmse 14-24, cdr 1 or 2 at screening * clinical diagnosis of dementia, due probably to ad, by revised national institute on aging-alzheimer's association criteria (mckhann, 2011) * body mass index (bmi) of ≥ 18 and ≤ 35 kg/m2 at screening * reliable and capable support person/caregiver * treatment-free (subjects not receiving acetylcholinesterase inhibitor \[achei\] treatment), defined as: * treatment-naïve, or * subjects who received an achei in the past and discontinued at least 4 weeks prior to screening key exclusion criteria: * history of significant neurologic disease, other than ad, that may affect cognition, or concurrent with the onset of dementia * subject has atypical variant presentation of ad, if known from medical history, particularly non-amnestic ad * history of brain mri scan indicative of any other significant abnormality * diagnosis of severe major depressive disorder even without psychotic features. * significant suicide risk * history within 2 years of screening, or current diagnosis of psychosis * myocardial infarction or unstable angina within the last 6 months * clinically significant cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (note: pacemaker is acceptable) * subject has either hypertension or symptomatic hypotension * clinically significant ecg abnormality at screening * chronic kidney disease with estimated glomerular filtration rate (egfr) \<45 ml/min * hepatic impairment with alanine aminotransferase or aspartate aminotransferase \> 2 times the upper limit of normal, or child-pugh class b and c * malignant tumor within 3 years before screening * memantine in any form, combination or dosage within 4 weeks prior to screening * acetylcholinesterase inhibitors in any dosage form * the subject has received active amyloid or tau immunization (i.e., vaccination for alzheimer's disease) at any time, or passive immunization (i.e., monoclonal antibodies for alzheimer's disease) within 6 months of screening

Keywords: alzheimer's disease cognition dementia ath-1017 lift ad fosgonimeton
step by step: a tailored walking intervention for breast cancer survivors

Conditions: Sedentary Lifestyle; Breast Neoplasms; Survival Rate (Survivorship)

Summary: this study aims to recruit post-treatment breast cancer survivors for a 12-week 2-arm randomized walking intervention. all intervention materials will be delivered electronically. the investigators hypothesize that at the end of 12-weeks, participants randomized to the intervention group will engage in more weekly steps than those participants randomized to the comparison group.

more than two-thirds of breast cancer survivors are physically inactive. inactivity is known to negatively impact both morbidity and mortality, and is especially pronounced among cancer survivors. self-directed interventions targeting inactivity among breast cancer survivors often report clinically insignificant behavior change. more successful behavior change interventions have suggested that tailoring and, more recently, the fostering of intrinsic motivation, may have improved outcomes. however, no interventions to date have utilized these approaches to increase physical activity among sedentary cancer survivors. aim 1: develop and test intervention (tailored) and comparison group (targeted) messages in a sample of sedentary women to determine message acceptability. aim 2: determine the efficacy of a 12-week tailored intervention to increase the number of weekly steps taken among sedentary post-treatment breast cancer survivors compared to a 12-week, targeted intervention.

Eligibility criteria:
inclusion criteria: * female * 40-70 years of age * history of breast cancer stage i-ii * 2-10 years post-treatment * sedentary * technology access and skills * regular access to personal computer/ broadband internet and email account * comfortability using internet, and web-based tools * us resident exclusion criteria: * concurrent enrollment in another physical activity/ lifestyle/ weight loss intervention program/study * current secondary cancer diagnosis/ treatment * inability to ambulate * refusal to wear personal activity monitor (fitbit ultra) for the duration of the study * engaging in regular moderate to vigorous physical activity
internet-delivered emotion regulation individual therapy for adolescents with nssi - an open pilot study

Conditions: Nonsuicidal Self-Injury

Summary: the primary aim is to investigate the effectiveness of an internet-delivered emotion regulation individual therapy for adolescents (erita) with nonsuicidal self-injury (nssi).


Eligibility criteria:
inclusion criteria: a primary diagnosis of nssi as defined in section 3 in the fifth edition of the diagnostic and statistical manual 5 of the american psychiatric association (dsm-5) \< 1 nssi episode during the past month at least one parent needs to commit to participate in the parent program exclusion criteria: bipolar disorder i or primary psychosis severe suicidal ideation ongoing substance dependence insertion/withdrawal of psychopharmacological substances within two months prior to the treatment other acute primary axis i diagnosis (e.g. anorexia nervosa) that demand treatment in first hand current life circumstances that would hinder the treatment (i.e. ongoing domestic abuse) insufficient swedish language skills cocurrent treatment with mentalization based therapy (mbt) or dialectical behavioral therapy (dbt)

Keywords: nonsuicidal self-injury (nssi), deliberate self-harm (dsh), self-harm, self-injury
effect of cervical epidural steroid injection with neural mobilization in patients with cervical radicular pain

Conditions: Cervical Pain

Summary: this study examines the effectiveness of cervical epidural steroid injections (cesi) and neural mobilization (nm), individually and in combination, in alleviating cervical radicular pain-a condition characterized by nerve root compression or irritation often due to herniated discs or bony spurs. cervical radiculopathy leads to chronic pain, sensory and motor deficits, and disability in the upper limbs.

the study is a randomized controlled trial conducted between april and october 2024, with patients diagnosed with cervical radicular pain randomized into three groups: cesi-only, nm-only, and combined cesi and nm.

Eligibility criteria:
inclusion criteria: * adults aged 18-65 years, diagnosed with chronic cervical radicular pain. * patients with chronic cervical radicular pain (\>6 months). * patients who had been confirmed through clinical examination and imaging studies (mri or ct) showed evidence of nerve root compression. * participants were included if they provided written informed consent, demonstrated the ability to adhere to the study protocol, and committed to attending follow-up appointments while completing the required outcome measures. exclusion criteria: * patient refusal. * patients above the age of 65 were eliminated to reduce confounding by age-related health concerns and to provide a more homogenous study population for more accurate treatment outcomes. * patients with a history of cervical spine surgery, uncontrolled diabetes mellitus, hypertension ischemic heart disease, and pregnancy * patients with chronic pain syndromes that may interfere with cervical radicular pain evaluation, such as fibromyalgia, rheumatoid arthritis, or hypersensitivity, will be excluded. these disorders will be evaluated during screening using a complete medical history review, physical examination, and precise diagnostic criteria to guarantee correct detection of cervical radicular discomfort.
evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis

Conditions: Hypersensitivity Pneumonitis

Summary: this study aims to evaluate the efficacy of pirfenidone in chronic hypersensitivity pneumonitis. this study included 40 adult patients (≥ 18 years) with a diagnosis of chronic progressive hypersensitivity pneumonitis. the included patients were divided into 2 groups 20 patients in each one. group 1: will receive pirfenidone in addition to the conventional treatment group 2: will be maintained on conventional treatment. forced vital capacity (fvc),6 minutes walking test(6mwt), oxygen tension in the arterial blood (pao2), and st. george's respiratory questionnaire (sgrq ) were measured before and after 6 months of a pirfenidone treatment trial. results

rationale the present data about the treatment of chp are few and largely based on observational studies and expert opinion. it is suggested that pirfenidone may slow disease progression in cases of chp as it has some anti-inflammatory in addition to antifibrotic effects. hypothesis pirfenidone will slow disease progression in hypersensitivity pneumonitis patients research questions 1. can pirfenidone slow disease progression in cases of chp? 2. what about the safety of pirfenidone in cases of chp? this study aims to evaluate the efficacy of pirfenidone in chronic hypersensitivity pneumonitis. objectives 1. to compare the functional and radiological parameters between patients group who receive pirfenidone treatment and the patient group who receive conventional treatment: fvc, 6 minutes walking distance, the partial pressure of oxygen in arterial blood ( pao2), pulmonary artery systolic pressure, st.george's respiratory questionnaire(sgrq score) and quantitative ild score (qild), by quantitative hrct chest. 2. to compare the side effects between patients' group who receive pirfenidone treatment and the patient group who receive placebo treatment study design an interventional randomized controlled study

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years old with a diagnosis of chronic progressive hypersensitivity pneumonitis: * \>10% extent of fibrosis (eg, reticulation) on high-resolution ct (hrct) scan * absolute decline in fvc% predicted \>5% within the previous 6 months despite conventional treatment. exclusion criteria: * pregnancy or breastfeeding period * patients with peptic ulcer, severe hepatic disease, severe kidney disease, severe cardiac disease, and patients with other chronic pulmonary diseases. * presence of active infection * history of alcohol or drugs abuse * active smokers